CytoMed Therapeutics Limited Ordinary Shares

Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this...

Related tickers: NFLX, GS, MS, BAC, UNH, JNJ, TRV, PG, AXP, SCHW, MTB, RIO, UAL, ABT, USB, KMI, VFS, LVS, CSX, BX, ALLY, TSM, ISRG, NKLA, RIVN, IZM, GALT, PERI, SIRI, GL, CPRI, TPR, ALAB, RDDT, AUNA, WBUY, GDTC, SONY, VZ, SBGI, BMR, IDCC, BLZE, BIDU, GP, BNTC.

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has obtained board approval to launch, subject to certain terms and conditions, a pilot program (“Program”) to isolate and cryo-store peripheral blood mononuclear cells (“PBMCs”) for and as a reward to loyal shareholders of CytoMed on a complimentary basis. This Program is in line with the Company’s strategy to build up a private bank of PBMC donors to develop allogeneic off-the-shelf cellular therapies using pre-qualified healthy donor blood. This Program will commence on June 1, 2024, or at such other date as CytoMed shall provide. Interested shareholders are advised to refer to CytoMed’s website for any future updates regarding the Program.

Related tickers: GDTC.